Stoke Therapeutics (STOK) Other financing activities (2018 - 2026)

Stoke Therapeutics' Other financing activities history runs 9 years deep, the most recent figure standing at $3.2 million for Q1 2026.

• On a quarterly basis, Other financing activities rose 219.22% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $10.8 million, a 336.35% increase from a year earlier, with the FY2025 full-year figure at $8.6 million, up 399.59% from the prior year.
• Other financing activities declined to $3.2 million in Q1 2026 per STOK's latest filing, from $7.6 million in the prior quarter.
• Across five years, Other financing activities topped out at $7.6 million in Q4 2025 and bottomed at -$634000.0 in Q2 2025.
• The 5-year median for Other financing activities is $161000.0 (2023), against an average of $851235.3.
• Across the five-year window, Other financing activities jumped 29650.0% in 2024 and slumped 673.17% in 2025, its largest moves.
• Year by year, Other financing activities stood at $118000.0 in 2022, then slumped by 96.61% to $4000.0 in 2023, then soared by 29650.0% to $1.2 million in 2024, then soared by 538.74% to $7.6 million in 2025, then tumbled by 57.83% to $3.2 million in 2026.
• Per Business Quant, the three latest STOK Other financing activities figures stand at $3.2 million (Q1 2026), $7.6 million (Q4 2025), and $632000.0 (Q3 2025).